This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

POLX.F Stock Overview

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. More details

POLX.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings have declined by 74.3% per year over past 5 years

Does not have a meaningful market cap ($7M)

Does not have meaningful revenue ($5M)

My Notes

Capture your thoughts, links and company narrative

Polydex Pharmaceuticals Limited Competitors

Aytu BioPharma

NasdaqCM:AYTU

US$10.3m

CordovaCann

OTCPK:LVRL.F

US$4.9m

TherapeuticsMD

NasdaqGS:TXMD

US$12.5m

Biofrontera

NasdaqCM:BFRI

US$8.2m

Price History & Performance

Summary of share price highs, lows and changes for Polydex Pharmaceuticals
Historical stock prices
Current Share Price	US$1.99
52 Week High	US$2.01
52 Week Low	US$0.55
Beta	0.45
1 Month Change	-1.19%
3 Month Change	6.20%
1 Year Change	175.83%
3 Year Change	130.93%
5 Year Change	89.14%
Change since IPO	-90.37%

Recent updates

Shareholder Returns

	POLX.F	US Pharmaceuticals	US Market
7D	0.3%	2.3%	-0.9%
1Y	175.8%	4.3%	22.6%

Return vs Industry: POLX.F exceeded the US Pharmaceuticals industry which returned -4.4% over the past year.

Return vs Market: POLX.F exceeded the US Market which returned 15.2% over the past year.

Price Volatility

Is POLX.F's price volatile compared to industry and market?
POLX.F volatility
POLX.F Average Weekly Movement	6.1%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: POLX.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine POLX.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1979	20	George Usher	www.polydex.com

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry.

Polydex Pharmaceuticals Limited Fundamentals Summary

How do Polydex Pharmaceuticals's earnings and revenue compare to its market cap?
POLX.F fundamental statistics
Market cap	US$6.82m
Earnings (TTM)	-US$842.27k
Revenue (TTM)	US$4.74m

1.4x

P/S Ratio

-8.1x

P/E Ratio

Is POLX.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
POLX.F income statement (TTM)
Revenue	US$4.74m
Cost of Revenue	US$4.60m
Gross Profit	US$142.86k
Other Expenses	US$985.13k
Earnings	-US$842.27k

Last Reported Earnings

Apr 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.25
Gross Margin	3.01%
Net Profit Margin	-17.76%
Debt/Equity Ratio	2.8%

How did POLX.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/08/07 19:03
End of Day Share Price	2023/08/07 00:00
Earnings	2023/04/30
Annual Earnings	2023/01/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Polydex Pharmaceuticals Limited is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Polydex Pharmaceuticals OTCPK:POLX.F Stock Report